GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (5)
  • Bae, Hyun Joo  (5)
Material
Publisher
  • American Association for Cancer Research (AACR)  (5)
Language
Years
Subjects(RVK)
  • 1
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 82, No. 12_Supplement ( 2022-06-15), p. 5972-5972
    Abstract: Purpose: Fibroblast growth factors (FGFs) and fibroblast growth factor receptors (FGFRs) are implicated in tumor angiogenesis. Although erdafitinib showed efficacy in urothelial carcinoma (UC) patients harboring FGFR pathway alteration, the anti-angiogenic activity of this compound remains uncertain. Here, we investigated the suppression of UC growth by inhibiting angiogenesis with erdafitinib both in vitro and in vivo. Materials and Methods: The inhibitory effect of erdafitinib on UC cells was evaluated by wound healing assay, transwell invasion assay, and zymography assay. Tubule formation assay and transwell migration assay was conducted to assess inhibitory effect of erdafitinib on endothelial cells (EC). Transwell migration assay to assess crosstalk of EC co-cultured with UC cell was also performed. For in vivo study, athymic nude mice bearing RT4 cells were randomly divided into a control group, and erdafitinib group. Tumors were then extracted for analysis such as immunohistochemistry. Results: The results of wound healing assay and transwell invasion assay demonstrated that erdafitinib has inhibitory actions on the migratory and invasive potential of UC cells. Erdafitinib also suppressed tube formation and migratory potential of ECs. Transwell migration assay using EC co-cultured with RT4 showed that migration of EC was significantly inhibited by erdafitinib. For in vivo experiments, immuno-deficient mice (N=14) bearing RT4 xenografts were treated with or without erdafitinib (40mg/kg) orally three times a week for three weeks, and erdafitinib significantly suppressed tumor volumes and weight by 60.0% and 24.4%, respectively. The decrease of both CD31-positive and Ki-67-positive cells indicated that erdafitinib exerted anti-angiogenic activity. Conclusion: This study demonstrated that erdafitinib has anti-angiogenic activities both in vitro and in vivo. It warrants further investigation for development of new therapeutic strategy. Citation Format: Seungtaek Lim, Sun Young Rha, Hyun Joo Bae, Sang Woo Cho, Jii Bum Lee, Tae Soo Kim, Sun Kyung Kang, Woo Sun Kwon, Nam Hoon Cho, Young Deuk Choi, Kunhong Kim, Hoi Young Lee. Antiangiogenic activity of FGFR inhibitor erdafitinib in urothelial carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5972.
    Type of Medium: Online Resource
    ISSN: 1538-7445
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2022
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2018
    In:  Cancer Research Vol. 78, No. 13_Supplement ( 2018-07-01), p. 2302-2302
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 78, No. 13_Supplement ( 2018-07-01), p. 2302-2302
    Abstract: Dysregulation of cell cycle is a hallmark of cancer and the p16INK4a-CDK4/6-Rb pathway is often disrupted in many types of cancer including gastric cancer. Inhibition of CDK4/6 in cancer cells has become a promising therapeutic strategy, but not tested in gastric cancer. In this study, we investigated the effect of abemaciclib (LY2835219), a dual inhibitor of CDK4 and CDK6, and identified potential biomarkers in 49 gastric cancer cell lines. The cytotoxicity of abemaciclib was assessed by CCK-8 assay. For exploration of predictive biomarkers, status of single nucleotide variants (SNVs) and copy number variations (CNVs) were analyzed by whole exome sequencing (WES). Also, RNA and protein expression levels of cell cycle related molecules were determined by RNA sequencing and Western Blot, respectively. In TCGA study (The Cancer Genome Atlas, Nature 2017) approximately 37% of stomach adenocarcinoma patients have defects in the p16INK4a-CDK4/6-Rb pathway (143/388patients); notable signatures include alterations of p16INK4a (14%), Rb1 (7%), CDK4 (4%), CDK6 (8%), cyclinD1 (6%), and cyclinE1 (12%). In our 49 gastric cancer cell lines, we confirmed 25 cell lines have defects in this pathway (51%) including alterations of p16INK4a (38%), Rb1 (10%), CDK6 (8%), cyclinD1 (4%), and cyclinE1 (2%). Based on the sensitivity of abemaciclib, we could divide 49 gastric cancer cell lines into: sensitive (IC50 & lt;0.5uM, 28/49 cell lines) and resistant (IC50≥0.5uM, 21/49cell lines) groups with the cut off 0.5uM which was determined by clinically achievable concentration from phase I trial. As a result of relation analysis between protein expression and sensitivity of abemaciclib, p16INK4a deletion did not correlate with sensitivity. Then, correlation analysis between sensitivity and RNA expressions of p16INK4a-CDK4/6-Rb pathway related genes were determined. Significant correlations were found in p16INK4a (r=0.4783, p=0.0016), Rb1 (r=-0.3206, p=0.0410), and cyclinE1 (r=0.5378, p=0.0003) whereas not in cyclinD1, CDK4, and CDK6. Protein expression levels of p16INK4a and cyclinD1 were not related to sensitivity of abemaciclib. In addition, with reproduction of the GDSC (Genomics of Drug Sensitivity in Cancer) information, focal recurrent copy number alterations of regions of chromosome 9p24.3-p21.1 (cnaPANCAN144) were correlated with CDK4/6 inhibitor sensitivity. Among ninety-one genes within these regions, 16 genes from cnaPANCAN144 were correlated with sensitivity of abemaciclib (p≤0.05). Our results indicate that abemaciclib is a potential therapeutic agent for gastric cancer and demonstrate that RNA expressions of p16INK4a, Rb1, and cyclinE1 would be predictive biomarkers based on molecular genetic profiling. Citation Format: Hyun Joo Bae, Woo Sun Kwon, Hyun Jeong Kim, Sun Kyoung Kang, Inhye Jeong, Tae Soo Kim, Hyun Cheol Chung, Sun Young Rha. Preclinical evaluation of CDK4/6 inhibitor and biomarker exploration in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2302.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2018
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 2973-2973
    Abstract: Gastric cancer (GC), the second leading cause of cancer-related deaths worldwide, is especially prevalent in Asian countries. Despite advances in therapeutics, GC patients with peritoneal metastasis is frequent and when ascites has developed, the prognosis is very poor. Also, the number of anticancer drugs successfully marketed is rare in GC. Therefore, a faithfully in vitro model that can test various drugs and perform patient-specific personalized therapy is needed. We isolated cancer cells from ascites or pleural fluids of gastric cancer patients and established 19 patient-derived organoids and matched patient-derived cancer cell lines (PDCC). Organoid success rate was 60.7 % while PDCC was about 28.5 %. The time required to establish organoids was 1-2 months, while PDCC was 3-4 months. Organoids showed various growth characteristics and morphology, which reflects the clinical behavior of the patients including adenocarcinoma or signet ring cell carcinoma. In addition, drug-sensitive to each organoid and matched PDCC were identified using various chemotherapeutics and targeted agents. Then, patients' clinical information and comparative analysis were performed, suggesting the potential sensitive drug to each patient. Currently, the genetic information of each organoid is ongoing with WES/RNA Seq, and the sensitivity and comparative analysis of the drug will be performed. Therefore, our results provide a potential infrastructure for personalized therapy by comprehensive analysis of the patient's genomic data and organoid/PDCC model. Citation Format: Sun Kyoung Kang, Hyun Joo Bae, Woo Sun Kwon, Tae Soo Kim, Sujin Lee, Sang Woo Cho, Hyun Cheol Chung, Sun Young Rha. Establishment of organoids and patient derived cancer cell lines from gastric cancer body fluids as preclinical models for personalized therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2973.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2021
    In:  Cancer Research Vol. 81, No. 13_Supplement ( 2021-07-01), p. 945-945
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 945-945
    Abstract: Trastuzumab, a humanized anti-HER2 monoclonal antibody, has shown clinically significant benefits for HER2-positive GC patients. Also, all anti-HER2 agents approved by the FDA are used for HER2-positive. However, since HER2-positive is only 10-20% of GC, targeted therapies for non-HER2-positive GC is needed. To overcome these limitations, antibody-drug conjugates (ADCs), which directly deliver cytotoxic drugs to cancer cells, have been developed. T-DXd (Daiichi Sankyo, Japan), an anti-HER2 ADC, can induce the death of neighboring cells because it has a bystander killing effect due to the high membrane permeability of the payload. However, biomarkers for predicting drug response have not yet been studied other than HER2 overexpression/amplification. In this study, we investigated the correlation between HER2 expression level and anti-tumor effect of T-DXd in a 49 GC cell line panel and the HER2-associated molecules related to T-DXd sensitivity. For HER2 status, we analyzed multiple genetic and molecular characteristics using WES, SISH, IHC, flow cytometry, and immunoblotting. GC cell lines (n=49) were divided into 3 groups according to the HER2 expression level through flow cytometry using 4 breast cancer cell lines (SK-BR-3, ZR-75-1, MCF-7, and HCC1937) for quantitative control. Groups with HER2 over- and moderate/low-expression were characterized with higher expression levels compared to ZR-75-1 (HER2 2+) and HCC1937 (HER2-negative), respectively. HER2 non-expression had lower expression levels compared to HCC1937. The sensitivity of T-DXd was evaluated in 49 GC cell lines by cell viability assay. The inhibition rate of T-DXd was calculated at 10 µg/ml. Also, expression levels of RTKs were determined by immunoblotting, and HER2 extracellular domain (ECD) and NRG1 expression were evaluated by ELISA. GC cell lines were divided into 6 HER2 over-, 26 HER2 moderate/low-, and 17 HER2 non-expression cell lines. As expected, HER2 over-expression cell lines were sensitive to T-DXd (5/6, 83.3%). T-DXd also had anti-tumor effects in the HER2 moderate/low-expression cell lines (12/26, 46.2%). There were correlations between HER2 expression level and anti-tumor effect of T-DXd in both HER2 over and moderate/low-expression cell lines. HER2 over and moderate/low-expression cell lines with high HER2 ECD expression were sensitive to T-DXd. NRG1 had relatively low expression in all GC cell lines and was not correlated with T-DXd. Additionally, even HER2 non-expression cell lines were sensitive to T-DXd (10/17, 58.8%). We found that HER2 non-expression cell lines had an RTK amplification (9/17, 52.9%) and among those cell lines, MET amplified cells showed sensitivity to T-DXd. Currently, the evaluation of the underlying mechanisms is ongoing. Our results indicate that T-DXd shows efficacy in HER2-amplified GC cell lines, HER2 moderate/low-expression, and some cell lines with HER2 non-expression. Citation Format: Seo Young Yu, Juin Park, Woo Sun Kwon, Inhye Jeong, Sun Kyoung Kang, Hyun Joo Bae, Tae Soo Kim, Hyun Cheol Chung, Sun Young Rha. Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 945.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 81, No. 13_Supplement ( 2021-07-01), p. 2055-2055
    Abstract: One of the many causes of cancer is a dysfunction of the DNA damage repair (DDR) pathway. Cancers with alterations in homologous recombination (HR) genes are known to be increased the sensitivity of PARP inhibitors and genomic instability. Besides, cancers with alterations in other DDR genes like mismatch repair (MMR), have been recently reported to have similar features. Furthermore, some studies suggested that hypermutated cancers, such as microsatellite instability-high (MSI-H) or tumor mutational burden (TMB) high, have DDR gene alterations. Nevertheless, many studies still have focused on HR-related gene alteration as a predictor of olaparib. Here, we aim to determine if the DDR gene alteration and genomic instability markers can predict olaparib efficacy in 49 gastric cancer cell lines. First, we profiled the genomic status of 48 DDR genes, MSI status, and TMB using targeted sequencing (524 genes). BRCA1, RAD51C, and MLH1 methylation were detected by bisulfite sequencing. If cell lines had the deleterious mutation, homozygous deletion, or methylation in DDR genes, it was categorized as an alteration group. To determine the efficacy of olaparib, cell lines were treated with olaparib for 5 days and assessed by CCK-8 assay. IC50 values were determined by the CalcuSyn software and cell lines were classified as a sensitive group when the IC50 was less than 10µM. MMR-related and PARP1 protein expression was determined by western blot. As a result, 17 cell lines had the alteration in one or more of the 18 DDR-related genes. In our cell line panel, the expression of PARP1 protein was varied, and 12 cell lines were sensitive to olaparib. DDR alteration group was more sensitive to olaparib than the DDR wild type group (median of IC50 = 14.08µM vs & gt; 20µM, p = 0.034). In detail, cell lines with alterations in the HR and MMR were significantly sensitive among the subtype of DDR pathways (p = 0.011, p = 0.009). TMB was widely distributed among the GC cell lines (range = 4.36 to 21.80, median = 10.90), and the DDR alteration group had higher TMB than DDR wild type group (median = 11.63 vs 10.90, p = 0.029). Interestingly, the olaparib sensitive group had higher TMB than the resistant group (median = 15.3 vs 10.9, p & lt; 0.0001). Four cell lines (SNU-1, SNU-638, IM95m, and NUGC-3) were MSI-H, and all of them were no MLH1 protein expression. MSI-H cell lines had significantly higher TMB than other cell lines (median=19.3, p & lt; 0.0001). Three MSI-H cell lines were sensitive to olaparib, but NUGC-3 with the lowest TMB (13.8) among MSI-H cell lines was resistant. In our result, the olaparib sensitive group had the alteration in DDR genes and high TMB. MSI-H cell lines were sensitive to olaparib when it had high TMB. MSI status and TMB could predict olaparib sensitivity in gastric cancer as well as DDR gene alterations. Citation Format: Jihyun Hwang, Woo sun Kwon, Juin Park, Hyun Joo Bae, Inhye Jeong, Sun Kyoung Kang, Tae Soo Kim, Jingmin Che, Hyun Cheol Chung, Sun Young Rha. Evaluation of DNA damage repair gene alterations, microsatellite instability status, and tumor mutational burden as predictive biomarkers of olaparib sensitivity in gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2055.
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2021
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...